ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
Ajanta Pharma achieved record FY26 revenue >₹5,000cr and PAT >₹1,000cr, driven by strong US and Africa performance despite Asia supply chain headwinds.
Ajanta Pharma hit major milestones in FY26, surpassing ₹5,000cr revenue and ₹1,000cr PAT, but faces logistics-driven volatility in Asia and rising costs from Middle East conflicts.